Takeda’s Hyqvia Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy
Japanese pharmaceutical company Takeda (TYO: 4502) has received an indication extension approval from the US...
Drug
Qilu Pharmaceutical’s Iruplinalkib Gains Additional Indication Approval in China for ALK-Positive NSCLC
The National Medical Products Administration (NMPA) website has indicated that Qilu Pharmaceutical’s Category 1 drug,...
Changchun High & New Technology Industries to Launch GenSci125 Phase I Trial in US
Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading Chinese pharmaceutical company,...
Hengrui Pharmaceuticals Receives NMPA Approval for Phase II Cervical Cancer Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...
Roche’s Tecentriq SC Receives European Nod as First Subcutaneous PD-(L)1 Therapy
Halozyme Therapeutics (NASDAQ: HALO) has announced that the European Commission (EC) has granted marketing authorization...
Sino Biopharmaceutical Commences Phase III Trial for Semaglutide Biosimilar in China
Sino Biopharmaceutical Ltd (HKG: 1177), a leading Chinese pharmaceutical company, has announced the initiation of...
Yifan Pharmaceutical Wins Nod for Generic Diazoxide Oral Suspension in China
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that it has...
RemeGen’s MSLN-Targeted ADC RC88 Clears to Begin Phase I/IIa Study in China
RemeGen Co., Ltd (HKG: 9995; SHA: 688331), a leading Chinese biotech firm, has announced that...
Drug Farm’s DF-003 Earns FDA Rare Pediatric Disease Designation for ROSAH Syndrome
Sino-US biotech company Drug Farm has announced that it has received Rare Pediatric Disease Designation...
InnoCare Pharma Receives US FDA IND Approval for BCL2 Inhibitor ICP-248
InnoCare Pharma (HKG: 9969; SHA: 688428), a China-based pharmaceutical company, has announced that it has...
Chipscreen NewWay Biosciences Initiates Phase I Trial for PD-1/CD40 Bispecific Antibody Candidate NWY001
China-based Chengdu Chipscreen NewWay Biosciences Co., Ltd has announced that the first patient has been...
3D Medicines Secures Registration for Envafolimab in Macau for Advanced Solid Tumors
3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the registration of its PD-L1...
Hope Medicine Initiates Phase II Trial for HMI-115 in Endometriosis Treatment
Hope Medicine Inc., based in China, has announced the first patient dosing in a global...
Neuboron Medtech Secures Clinical Trial Approval for First BNCT Drug in China
Neuboron Medtech Ltd., based in China, has received clinical trial approval for its borofalan (10b)...
SciClone’s Partner Menarini Files for Elacestrant Approval in Macau for Advanced Breast Cancer
SciClone Pharmaceuticals Inc. (HKG: 6600) has announced that its Italian partner, Menarini Group, has submitted...
Bayer’s Asklepios BioPharmaceutical Launches Phase II Trial for AAV Therapy in Heart Failure
Bayer’s (ETR: BAYN) gene therapy subsidiary, Asklepios BioPharmaceutical, has initiated patient recruitment for a Phase...
CanSino Biologics Enrolls First Patient in Phase I Trial of Innovative Polio Vaccine
CanSino Biologics (SHA: 688185, HKG: 6185), a China-based biotechnology firm, has announced the enrollment of...
RemeGen Secures Fast-Track Designation for RC88 in Platinum-Resistant Ovarian Cancer
China-based biotech RemeGen Co., Ltd (HKG: 9995; SHA: 688331) has received fast-track designation (FTD) from...
CSPC Pharmaceutical Secures FDA Approval for Clinical Study of JMT106 in GPC3-Positive Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received approval from the US FDA to...
MSD’s Keytruda Gains FDA Approval for Advanced Cervical Cancer Treatment
Merck, Sharp & Dohme (MSD; NYSE: MRK) has received regulatory approval from the US Food...